Ani Pharmaceuticals Intrinsic Value Calculator – ANI PHARMACEUTICALS Reports Second Quarter Earnings for FY2023
August 22, 2023
🌥️Earnings Overview
For the second quarter of FY2023, ANI PHARMACEUTICALS ($NASDAQ:ANIP) reported a total revenue of USD 116.5 million, up 57.8% from the same period in the prior year. This growth was accompanied by an increase in net income of 141.8%, amounting to USD 6.2 million. The quarter ended on June 30 2023.
Price History
The stock opened at $61.0 and closed at $61.1, representing a 9.2% increase from the previous closing price of $55.9. This positive news was met with enthusiasm from investors, as the stock was trading at its highest level in four months. This marked the first time in the company’s history that it achieved such high profits in a quarter. The strong results were attributed to ANI PHARMACEUTICALS’ focus on developing innovative products and expanding into new markets.
The company’s product portfolio is now more diverse than ever, as it now includes treatments for cancer, heart disease, and infectious diseases. The company’s presence in Latin America and Asia has also enabled it to reach new customers and increase its market share. The outlook for future quarters is very positive and investors can expect more good news in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ani Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 401.39 | -6.79 | 0.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ani Pharmaceuticals. More…
| Operations | Investing | Financing |
| 41.27 | -22.14 | 74.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ani Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 859.34 | 424.87 | 21.42 |
Key Ratios Snapshot
Some of the financial key ratios for Ani Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.7% | -15.0% | 4.7% |
| FCF Margin | ROE | ROA |
| 4.8% | 3.1% | 1.4% |
Analysis – Ani Pharmaceuticals Intrinsic Value Calculator
At GoodWhale, we have conducted a detailed analysis of ANI PHARMACEUTICALS‘ health, and our proprietary Valuation Line has given us a fair value of $42.2 per share. This means that ANI PHARMACEUTICALS’ stock is currently being traded at $61.1, representing an overvaluation of 44.7%. This discrepancy should be carefully considered by potential investors before they invest in ANI PHARMACEUTICALS. More…
Peers
The company’s products are available in a wide range of therapeutic areas, including cardiovascular, central nervous system, endocrine, gastrointestinal, and infectious diseases. ANI also offers a portfolio of branded products, which are marketed under the names ANI-Pulse and ANI-Q. The company’s competitors include Theratechnologies Inc, Cipher Pharmaceuticals Inc, Avadel Pharmaceuticals PLC.
– Theratechnologies Inc ($TSX:TH)
The company’s market cap is 248.32M as of 2022 and its ROE is 182.08%. The company is engaged in the research, development and commercialization of therapeutic solutions for people living with rare diseases. The company’s products include Tremegus, a treatment for hemophilia A; Trelegy, a treatment for COPD; and Tevagus, a treatment for Huntington’s disease.
– Cipher Pharmaceuticals Inc ($TSX:CPH)
Cipher Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutics for the treatment of dermatologic and neuropsychiatric diseases in Canada and the United States. The company was founded by Robert Tessier and Shawn Patrick O’Neil in December 1999 and is headquartered in Mississauga, Canada.
– Avadel Pharmaceuticals PLC ($NASDAQ:AVDL)
Adaval Pharmaceuticals PLC is a publicly traded company with a market capitalization of 354.4 million as of 2022. The company has a return on equity of -245.41%. Adaval is a pharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of central nervous system disorders.
Summary
ANI Pharmaceuticals has reported strong second quarter results for the fiscal year ending June 30 2023, with revenue increasing 57.8% and net income up 141.8%. The stock price was seen to move up on the same day. With such impressive numbers, investors should take a closer look at ANI Pharmaceuticals for potential long-term growth opportunities. The company appears to be in a good position to capitalize on the growing demand for its products, with strong revenue growth and high net income margins.
The stock should also benefit from higher demand for pharmaceuticals due to the current health crisis. Investors should keep an eye on ANI Pharmaceuticals as it may be an interesting option for both short and long-term investing.
Related Posts
Recent Posts
